James Mulay Sells 1,964 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the transaction, the director directly owned 654 shares of the company’s stock, valued at $39,318.48. This trade represents a 75.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Mulay also recently made the following trade(s):

• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00.

CG Oncology Trading Up 0.2%

NASDAQ:CGON opened at $60.43 on Thursday. The firm has a market capitalization of $5.33 billion, a PE ratio of -25.94 and a beta of 0.31. The stock has a 50 day moving average of $64.60 and a 200-day moving average of $56.95. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $75.50.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, analysts predict that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CGON has been the subject of several recent research reports. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. upped their target price on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Royal Bank Of Canada upped their target price on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Wedbush increased their price objective on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a report on Monday, May 18th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGON. JPMorgan Chase & Co. lifted its position in CG Oncology by 321.3% in the third quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock worth $9,179,000 after purchasing an additional 173,785 shares during the period. Vanguard Group Inc. lifted its position in CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after purchasing an additional 670,770 shares during the period. Mangrove Partners IM LLC lifted its position in CG Oncology by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock worth $27,056,000 after purchasing an additional 116,575 shares during the period. Sivik Global Healthcare LLC acquired a new stake in CG Oncology in the fourth quarter worth approximately $1,453,000. Finally, HighVista Strategies LLC lifted its position in CG Oncology by 152.1% in the third quarter. HighVista Strategies LLC now owns 26,040 shares of the company’s stock worth $1,049,000 after purchasing an additional 15,712 shares during the period. 26.56% of the stock is owned by institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.